Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia by Hoed, Marissa A.H. den et al.
1564
ARTICLE
haematologica | 2015; 100(12)
Acute Lymphoblastic Leukemia
Introduction
As survival rates of children with acute lymphoblastic
leukemia (ALL) have substantially improved, the understand-
ing of both short- and long-term side effects of ALL treatment
has become increasingly important.1 Severe osteogenic side-
effects of ALL treatment include osteonecrosis2-11 and bone
mineral density (BMD) loss,12-17 which often occur during and
shortly after antileukemic treatment. Both side effects may
lead to adverse events, such as pain, fractures and consequent
movement disability.17,18
Osteonecrosis is a condition caused by compromised bone
vascularization which leads to several local processes, includ-
ing bone infarction, trabecular thinning, bone weakness,
edema within the bone, local infarction, and risk of subse-
quent adjacent joint destruction.19 Although some compo-
nents of antileukemic treatment, especially glucocorticoids,
are considered to play a critical role in the etiology of
osteonecrosis, the pathogenesis is not fully understood.20
We and others have shown that BMD is already low when
ALL is diagnosed, and that the final BMD loss at cessation of
ALL treatment is mainly determined by BMD values at the
start of treatment.17,21,22 This suggests that the disease itself and
genetic variation in genes that influence bone density may be
important risk factors for BMD loss. The final BMD loss is
also determined by treatment with certain drugs, e.g. corti-
costeroids23 and folate antagonists,24 irradiation, physical inac-
tivity, and nutritional deficiencies.25
Although osteonecrosis and BMD loss have been extensive-
ly investigated during and after treatment of pediatric ALL,6,15-
17 it is unknown whether these two osteogenic side effects
occur together in individual ALL patients, or whether they
may aggravate each other’s development.
In this study, we prospectively evaluated the occurrence of
symptomatic osteonecrosis and change in BMD in pediatric
ALL patients who were older than 4 years of age at diagnosis,
and treated according to the dexamethasone-based Dutch
Child Oncology Group (DCOG)-ALL9 protocol.6,7,26 Our aim
was to examine whether osteonecrosis and BMD decline
occur together and whether these two osteogenic side-effects
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Osteonecrosis and decline of bone density are serious side effects during and after treatment of childhood acute
lymphoblastic leukemia. It is unknown whether osteonecrosis and low bone density occur together in the same
patients, or whether these two osteogenic side-effects can mutually influence each other’s development. Bone den-
sity and the incidence of symptomatic osteonecrosis were prospectively assessed in a national cohort of 466
patients with acute lymphoblastic leukemia (4-18 years of age) who were treated according to the dexamethasone-
based Dutch Child Oncology Group-ALL9 protocol. Bone mineral density of the lumbar spine (BMDLS) (n=466)
and of the total body (BMDTB) (n=106) was measured by dual X-ray absorptiometry. Bone density was expressed
as age- and gender-matched standard deviation scores. Thirty patients (6.4%) suffered from symptomatic
osteonecrosis. At baseline, BMDLS and BMDTB did not differ between patients who did or did not develop
osteonecrosis. At cessation of treatment, patients with osteonecrosis had lower mean BMDLS and BMDTB than
patients without osteonecrosis (respectively, with osteonecrosis: -2.16 versus without osteonecrosis: -1.21, P<0.01
and with osteonecrosis: -1.73 versuswithout osteonecrosis: -0.57, P<0.01). Multivariate linear models showed that
patients with osteonecrosis had steeper BMDLS and BMDTB declines during follow-up than patients without
osteonecrosis (interaction group time, P<0.01 and P<0.01). We conclude that bone density status at the diagnosis
of acute lymphoblastic leukemia does not seem to influence the occurrence of symptomatic osteonecrosis. Bone
density declines from the time that osteonecrosis is diagnosed; this suggests that the already existing decrease in
bone density during acute lymphoblastic leukemia therapy is further aggravated by factors such as restriction of
weight-bearing activities and destruction of bone architecture due to osteonecrosis. Osteonecrosis can, therefore,
be considered a risk factor for low bone density in children with acute lymphoblastic leukemia.
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ABSTRACT
may influence each other’s development during treatment
for pediatric ALL.
Methods
Study population
This study is based on a subset of a previously described cohort.
The children (4-18 years old) had newly diagnosed ALL and were
treated in The Netherlands according to the Dutch Childhood
Oncology Group (DCOG) – ALL9 protocol between January 1997
and November 2004.17,26 As previously described, patients were
stratified into a non-high-risk treatment group and a high-risk
group.26 Briefly, high-risk criteria were: white blood cell count
higher than 50×109/L, T-cell immunophenotype, mediastinal
mass, central nervous system involvement, testicular involvement,
and genetic aberrations [translocation t(9;22), BCR-ABL1, or any
11q23/MLL gene rearrangements]. All other patients were classi-
fied as non-high risk. The 2-year treatment schedules included
dexamethasone during an induction period of 6 weeks, and
repeated pulses of dexamethasone for 2 weeks every 7 weeks dur-
ing maintenance therapy (total cumulative dose: high-risk, 1,244
mg/m2; non-high-risk, 1,370 mg/m2). None of the patients received
irradiation to the central nervous system.26
For the current study, patients were prospectively evaluated
from diagnosis until 1 year after cessation of treatment, and data
were obtained from case report forms, which were collected cen-
trally by the DCOG. For patients who did not complete the ALL9-
protocol (because of toxicity, relapse, hematopoietic stem-cell
transplantation, or death), data before going off study were includ-
ed in the database. Patients with syndromes or pre-existent dis-
eases affecting BMD were excluded (Online Supplementary Figure
S1). The ethical review boards approved the study (trial number
NTR460/SNWLK-ALL-9) and written informed consent according
to the Helsinki agreement was obtained from all parents and from
patients ≥12 years old.
Outcome measures
Bone mineral density
BMD was measured at diagnosis (T0), after 32 weeks of treat-
ment (T1), at the end of the treatment protocol (T2, 109 weeks)
and 1 year after cessation of therapy (T3) (Figure 1).7 As previously
described,17,22 only pediatric ALL patients who were 4 years of age
and older at T3 were included for dual energy X-ray absorptiom-
etry measurements (DXA; by Lunar DPX-L scanner, Madison, WI,
USA or Hologic scanner, Waltham, MA, USA), as control BMD
values are only available for this age group. BMD of the lumbar
spine (BMDLS) was measured with a Hologic or Lunar DXA scan-
ner. In addition, in a subset of the cohort, BMD of the total body
(BMDTB) was measured with a Lunar DXA scanner in one treat-
ment center.17,22 DXA results of the Hologic scanner were com-
pared with the manufacturer’s own reference data and DXA
results of the Lunar scanner were compared with data from
healthy Dutch children, measured on the same scanner.27 Analyses
were performed with age- and sex-matched standard deviation
scores (SDS) of BMD, and BMD was categorized into BMD < -1
SDS and BMD < -2 SDS, as previously described.28,29
Osteonecrosis
Symptomatic osteonecrosis was defined as persistent pain in the
arms or legs, not resulting from vincristine administration, with
typical findings on magnetic resonance imaging.30,31 From here on,
we refer to symptomatic osteonecrosis as ON. ON was graded
according to the National Cancer Institute (NCI) Common
Terminology criteria for Adverse Events, version 3.0.32 As previ-
ously described,7 patients were considered as ON subjects when
they developed ON (NCI grade 2 to 4) during, or within the first
year after cessation of treatment. Magnetic resonance imaging
was performed of any anatomic location in which symptoms of
ON occurred. 
Fractures
All reported fractures were symptomatic, and confirmed by X-
ray. Fractures were included in the analyses when they were
reported between the day of ALL diagnosis and 1 year after dis-
continuation of therapy. Clinically significant fractures were
defined as vertebral compression fractures, fractures of long bones
in the lower limbs, and/or two or more fractures or fractures with-
out preceding trauma.17,33
Statistical analysis
To compare baseline characteristics between patients with and
without ON, or with and without a DXA scan, we used the chi-
squared (χ2) test for categorical variables, the two-sample t-test for
continuous variables with a normal distribution, and the Mann-
Whitney U test for continuous variables with a skewed distribution. 
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Figure 1. Comparison of sequential BMD measurements in pediatric
ALL patients (4-18 years of age) with and without ON. BMD of the (A)
lumbar spine (n=466) and (B) total body (n=106) in pediatric ALL
patients (4-18 years of age) with and without ON during and after the
treatment of pediatric ALL. The dots represent the mean and the
whiskers represent the standard error of the mean BMD. The “*” rep-
resents the comparison of BMD between patients with and without
ON and the “●” represents the comparison of BMD between patients
and the healthy population. Abbreviations: T0 = at diagnosis; T1 =
start of maintenance therapy (32 weeks); T2 = at cessation of therapy
(109 weeks); T3 = 1 year after cessation of therapy (161 weeks);
BMDLB = bone mineral density of the lumber spine; BMDTB = bone min-
eral density of total body; ΔT3-T0 = interaction group time * ON; **= P-
value <0.01; ***= P-value <0.001; ● = P<0.05.
A
B
The one-sample t-test was used at each time point (T0 to T3) to
compare BMD SDS measurements of ALL patients with reference
values of healthy children. The two-sample t-test was used to
compare BMD SDS measured at all the different time points
between patients with or without ON. The χ2 test was used to
examine whether patients with ON had BMD <-1 SDS, BMD <-2
SDS or fractures at cessation of treatment more often than patients
without ON. If numbers in the χ2-test analyses were smaller than
5, the Fisher exact test was used.
To analyze differences of BMD SDS change during total follow-
up (ΔT0-T3) between patients with and without ON, a linear
mixed model was used with an unstructured repeated covariance
type. The model was defined as “follow-up time”, “ON” and the
interaction variable “follow-up time*ON”. Differences in BMD
change between ON-positive and ON-negative patients at each
moment were estimated using a model without intercept defined
by the interaction variable “follow-up time*ON”.
For the multivariate analyses we verified that there was no over
adjustment by the additional variables age and risk group, because
they could be correlated with each other or ON incidence.6,17 This
was done by testing collinearity, which is not present when the
variance inflation factor is <10 in regression models with ON inci-
dence, age or risk group. The variance inflation factor provides an
index that measures the amount of bias associated with over
adjustment.34 The multivariate linear mixed model with BMD
change as an outcome measure included the variables: “follow-up
time”, “ON”, “age at diagnosis”, “risk group”, “follow-up time*risk
group”, “ON*risk group”, and “follow-up time*ON*risk group”. A
P-value ≤0.10 of the interaction variable was considered statistical-
ly significant. For these analyses, age at diagnosis was used as a
continuous variable. 
To examine effect modification by age and risk group, we also
performed stratified analyses by age and/or risk group. The inter-
action terms “age”, “age*ON”, and “follow-up time*age*ON”, and
“risk group”, “risk group *ON”, and “follow-up time* risk group
*ON” were added to the univariate model. For these analyses, age
was dichotomized into age <10 years and age ≥10 years. 
To support the previous analyses, we also used an alternative
analysis to examine whether patients with ON had greater bone
loss than patients without ON. For each patient with ON, we ran-
domly selected four control patients without ON.35,36
Subsequently, BMD measurements of each ON patient and their
controls were divided into measurements before the detection of
ON (M=-2, M=-1) and measurements after the detection of ON
(M=+1, M=+2). A paired sample t-test was used to examine the
BMD change before and after the moment that ON occurred in
the patients with ON, and their controls. To study whether this
BMD change (M=-1 to M=+1) was dependent on ON occurrence
and thus independent of the amount of treatment received, the
two-sample t-test was used to compare BMD change (M=-1 to
M=+1) between patients with ON and the selected controls with-
out ON. 
Statistical analyses were performed with SPSS 20.0 (SPSS Inc.,
Chicago, IL, USA) and, unless stated otherwise, P-values ≤0.05
(two-sided) were considered statistically significant. 
Results 
Seven hundred and fifty-one patients were treated
according to the DCOG-ALL9 protocol, of whom 58 were
excluded because of pre-existing conditions (n=35), lack of
follow-up data (n=20), or other miscellaneous reasons
(n=3). Of the remaining 693 patients, 575 were older than
4 years (Online Supplementary Figure S1), and DXA scans
were available for 466 of them. Patients with a DXA scan
(n=466) did not differ from patients without a DXA scan
(n=109) with regard to age >10 years (P=0.955), gender
(P=0.369), ON occurrence (P=0.312), ALL immunopheno-
type (P=0.472), risk protocol (P=0.822), or frequency of
clinically significant fractures (P=0.306). 
A subset of 332 of the 466 patients (72%) had a DXA
scan at the end of treatment (T2). DXA scans were
unavailable at T2 for a variety of factors: second malignan-
cy, death, relapse, progressive disease, stem cell transplan-
tation, treatment toxicity, loss of follow-up or issues relat-
ed to patients’ logistics. Patients with a DXA scan at T2
(n=332) were comparable to those without a DXA scan
(n=132) with regard to gender (P=0.640), prevalence of
ON (P=0.812), and clinically significant fractures
(P=0.364). However, patients without a DXA scan at T2
were older (percentage >10 years: 36% versus 24% in
those with DXA, P=0.009), were more often treated with
the high-risk protocol (41% versus 25%, P<0.001) and
more often had T-ALL (25% versus 12%, P=0.002).
Patients with a DXA scan at T3 (n=231) were comparable
to those without a DXA scan (n=235) with regard to gen-
der (P=0.534), age >10 years (P=0.148), prevalence of ON
(P=0.118), immunophenotype (P=0.122), risk protocol
(P=0.055) and clinically significant fractures (P=0.364). 
One patient had surgery due to a fracture of the right
femoral head with three pins, and since surgery may lead
to ON, we excluded this patient from the analyses from
that point onward.
Osteonecrosis
Thirty patients (6.4%) among the 466 included (>4
years) were diagnosed with ON in the period between
diagnosis and 1 year after cessation of ALL treatment. The
median time between diagnosis of ALL and occurrence of
ON was 14 months (range, 1-33 months). ON was diag-
nosed in weight-bearing joints of the lower limbs of all
affected patients;6 the joints involved were hips (n=19),
knees (n=22), and ankles (n=6). In five of the 30 patients,
ON was also diagnosed in the upper extremities [shoul-
ders (n=4), elbows (n=1) or wrists (n=1)]. Patients with
ON were significantly older than patients without ON
(P<0.001, Table 1). In 64% (n=18) of the patients
chemotherapy was adjusted because of ON; in eight
patients the use of corticosteroids was discontinued, in
seven patients the dose of corticosteroids was reduced,
and three patients were switched from dexamethasone to
prednisone. Every patient with ON had received instruc-
tions to reduce weight-bearing activities.
Bone mineral density
At cessation of treatment (T2), mean BMDLS was -1.28
SDS (SD: 1.27, n=332) and was significantly lower than
that in the patients’ healthy peers (P<0.01). In the single
center subset, BMDTB was -0.74 SDS (SD: 1.29, n=65) and
also significantly lower than that in the patients’ healthy
peers (P<0.01). 
Co-occurrence of osteonecrosis and low bone mineral
density 
BMDLS and BMDTB were not different at baseline
between patients who did or did not develop ON (T0:
mean BMDLS with ON -0.90 versus -1.14 without ON,
P=0.359 and mean BMDTB: with ON 0.07 versus 0.25 with-
out ON, P=0.650). At cessation of treatment (T2), patients
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with ON had significantly lower mean BMD than patients
without ON (T2: BMDLS -2.16 versus -1.21, P<0.001 and
BMDTB -1.73 versus -0.57, P=0.008, Figure 1). One year
after cessation of treatment, BMD in patients with ON
was again lower than in patients without ON (T3: BMDLS
with ON -1.68 versus -0.94 without ON, P=0.008; BMDTB
with ON -1.18 versus -0.42 without ON, P=0.019) (Figure
1). Patients with ON were also more likely to have BMD
<-1 SDS (T2: BMDLS with ON 90% versus 60% without
ON, P=0.004; BMDTB: with ON 90% versus without ON
33%, P<0.001) and BMD <-2 SDS (BMDLS with ON 62%
versus 25% without ON, P<0.001; BMDTB with ON 30%
versus 15% without ON, P=NA) than patients without ON
(Figure 2, Online Supplementary Figure S2).
Although patients with ON more often had a clinical
fracture during follow-up than patients without ON, this
difference was not statistically significantly different (with
ON: 12% versus without ON: 6%; P=0.165) (Table 1,
Figure 2). Of the four patients who had ON and a fracture,
two had a fracture related to trauma (talus; distal tibia
avulsion), one had vertebral collapse without preceding
trauma, and one had a fracture of the left tibial plateau
without preceding trauma 2 months after the diagnosis of
ON at the same location.
Bone mineral density change and osteonecrosis
The trend of BMDSDS change during follow-up was dif-
ferent between patients with and without ON, as the
interaction term between group (with ON versus without
ON) and BMD at a measurement time was significant
(interaction group time, BMDLS: P<0.001 and BMDTB:
P<0.001) (Figure 1). 
Correction for risk protocol and age at diagnosis
There was no overcorrection in the multivariate analy-
ses for BMDSDS change, because ON and age, ON or risk
group, and age and risk group were not collinear as the
variance inflation factor was <10. After correction for age
at diagnosis and risk group, BMD change during follow-up
was still significantly different for BMDLS and BMDTB in
patients with ON (interaction group time, BMDLS P<0.001
and BMDTB P=0.007) (Online Supplementary Figure S2). 
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Table 1. Characteristics of pediatric ALL patients (4-18 years of age) with and without ON.
Without ON (n=436) With ON (n=30)
N (%), median (range) N (%), median (range) P-value
Age at diagnosis
years 5.5 (1.0-16.6) 13.5 (5.0-17.1) <0.001a
Age group
<10 years 337 (77%) 2 (7%) <0.001c
≥10 years 99 (23%) 28 (93%)
Gender
male 277 (64%) 14 (47%) 0.065b
female 159 (36%) 16 (53%)
Immunophenotype
BCP-ALL 354 (85%) 25 (84%) 0.818
T-ALL 63 (15%) 5 (6%)
Risk group
non-high risk 310 (71%) 20 (67%) 0.605b
high risk 126 (29%) 10 (33%)
Clinically significant fractures during treatment 
no 392 (94%) 25 (86%) 0.165c
yes 25 (6%) 4 (14%)
aMann-Whitney U test; bChi-squared test; cFisher exact test;  ALL: acute lymphoblastic leukemia; BCP: B-cell precursor; ON: symptomatic osteonecrosis; n: number.
Figure 2. These area-proportional Venn diagrams represent the co-occurence of osteonecrosis, low BMD and fractures in pediatric ALL patients
with a BMD measurement at cessation of ALL treatement (T2). The numbers represent the absolute number of patients in each circle or zone.
Each zone is proportional to the absolute number of patients assigned to the zone. Abbreviations: BMDLB: bone mineral density of the lumber
spine; BMDTB:  bone mineral density of total body; SDS: standard deviation score; ON: symptomatic osteonecrosis; #: fractures.
A B C D
Effect modification by age and risk group
The interaction terms, “ON*risk group*follow-up time”
(interaction group time, BMDLS P=0.78 and BMDTB P=NA)
and “ON*age ≥10*follow-up time” (interaction group time,
BMDLS P=0.36 and BMDTB P=0.40) were not statistically
significant. Stratified analyses for age were only possible
in the group of patients ≥10 years, because there were too
few patients (only two) with ON in the group <10 years.
In the subgroup of patients ≥10 years, the BMD values
were lower in patients with ON than in patients without
ON, however the results were not statistically significant
and weakened by low numbers of patients (interaction
group time, BMDLS P=0.45 and BMDTB P=0.15, Online
Supplementary Figure S3). 
Stratified analyses for risk group showed that the differ-
ence seems to be more pronounced in the non-high-risk
group; however, patients treated with a high-risk protocol
also seem to have a lower BMD when they were diag-
nosed with ON during treatment (Online Supplementary
Figure S4). Stratified analyses for risk group in the sub-
group of patient ≥10 years of age were not possible
because the numbers in the high-risk group were too small
(patients with ON: n=10).
Time of osteonecrosis diagnosis as benchmark
To study the influence of ON occurrence on BMD loss,
we performed analyses using the randomly selected con-
trols. These analyses showed that BMD was not signifi-
cantly different between patients with or without ON at
the last DXA scan before the detection of ON (M=-1,
BMDLS P=0.402, BMDTB P=0.742) (Figure 3). Interestingly,
patients with ON had a significantly greater decline in
BMD after the detection of ON (between M=-1 to M=+1)
[mean BMDLS -0.43 (SD: 0.95), P=0.032; BMDTB -1.13 (SD:
0.28), P=0.004] (Figure 3). This mean BMD decline (M=-1
to M=+1) was more prominent in patients with ON than
in the randomly selected controls [BMDLS -0.43 (SD: 0.95)
versus 0.05 (SD: 1.06), P=0.046; BMDTB -1.13 (SD: 0.95) ver-
sus -0.17 (SD: 0.98), P=0.004] (Figure 3). This subsequently
resulted in a lower BMD in patients with ON than in con-
trols without ON at M=+1 (BMDLS, P=0.020; BMDTB,
P=0.015). 
Discussion
This prospective study emphasizes once again that
severe osteogenic side effects - such as ON and low BMD
- frequently occur during and after treatment for child-
hood ALL.6,15-17 The development of ON was not related to
BMD at the start of the antileukemic treatment.
Comparable data were found in one previous smaller
study of 38 patients that used quantitative ultrasound.37
In our cohort of children between 4-18 years old with
ALL, BMDLS and BMDLS were lower than in their healthy
peers, with values similar to those in most earlier
reports.15,16 Patients with ON had an even lower BMD at
the end of treatment compared to patients without ON. In
addition, we observed a steeper decline of BMD during
antileukemic treatment in patients with ON, even after
correction for age at diagnosis. This BMD decline occurred
especially after the diagnosis of ON. This suggests that
patients who develop ON during antileukemic therapy
may be in need of extra medical care for low BMD or
osteoporosis. Thus, low bone density and bone density
loss seem to be influenced by the occurrence of ON, as
well as previously identified factors such as age and
weight at diagnosis, B-cell-immunophenotype, use of cor-
ticosteroids, folate antagonists or irradiation, physical
inactivity, and nutritional deficiencies.17,21-25
Bone density loss in patients with ON is most likely
affected by a combination of avoidance of weight-bearing
activities and sports activities37 and by ON itself.38 Previous
studies in healthy volunteers and astronauts have shown
that “skeletal unloading” induces osteopenia,39-41 with a 3%
loss of BMD after 12 weeks.42 This might be due to a
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Figure 3. BMD measurements relative to the diagnosis of ON in pediatric ALL patients (4-18 years of age)  with ON as compared to randomly
selected controls without ON. BMD measurements relative to the diagnosis of ON for (A) lumbar spine BMD and (B) total body BMD. The line
and whiskers represent the mean and standard error of BMD. The dotted line per patient group represents the slope between measurements
before and after the diagnosis of ON. The BMD measurements from M=-2 to M=+2 can include BMD measurements at different time points
during treatment (T0 to T3). Δm = BMD change before and after the diagnosis of ON in the groups of patients with or without ON; ON-: patients
without ON; ON+: patients with ON.
BA
decrease in osteoblast recruitment and bone formation,43,44
as there is no stress of weight on these bones. BMD loss
may also occur due to ON itself; the fact that the BMDTB
decline seems to be more pronounced than the BMDLS
decline supports this idea. ON causes local destruction of
the bone,38 and ON is not usually located in the lumbar
spine, but it is located in bones measured by DXA of the
total body. 
It is unknown whether interventions may overcome the
negative influence of skeletal unloading and ON on the
decline of BMD. Weight-bearing activities may stimulate
BMD gain, but these activities need to be restricted in
patients with ON to avoid joint damage.11 Muscle training
without weight bearing to the vulnerable joints affected
by ON - such as swimming - improves physical perform-
ance; however swimming does not improve BMD.45,46
Further studies need to establish whether excessive BMD
loss could be prevented in patients with ON by other
interventions such as dietary supplementation with calci-
um, vitamin D and the use of bisphosphonates.11,47,48 Only
symptomatic patients were assessed in our study; howev-
er asymptomatic patients may also have bone destruction
and possible BMD loss. A recent report by Kaste et al.
described that early detection of ON with magnetic reso-
nance imaging in patients above the age of 10 is feasible;
these patients could then benefit from early therapy to
reduce BMD loss as well.10
Low BMD values were still present 1 year after cessa-
tion of treatment in patients who had ON, even though
some patients have radiological and clinical improvement
of ON.20 This is not surprising, as the effect of avoidance
of weight-bearing activities for several months is likely to
continue after cessation of treatment. Previous studies
have shown that bone loss or its destruction can recover,
although the recovery process is slow49 and during this
period there may be a high risk of fractures.17 We did not
find a higher risk of fractures in patients who had ON, but
this may be due to the low number of patients with frac-
tures in our study. 
One limitation of our study may be the fact that patients
who were older or who were treated with a high-risk
treatment protocol were more likely to be lost to follow-
up at the end of treatment. Furthermore, older age at diag-
nosis is a risk factor for a more rapid decline of BMSLS dur-
ing treatment and is also associated with an increased risk
of having ON.6,17
Although there was insufficient power to examine the
association between ON and BMD between age groups
and risk groups accurately, our findings indicate that ON
and BMD decline occur independently in any of these
groups. Since ON mainly occurs in the older group, it
would be worthwhile validating our findings in a large,
prospective study focusing particularly on children who
are older than 10 years of age.
We conclude with our preliminary findings that symp-
tomatic ON is accompanied by a decline in BMD during
antileukemic therapy in pediatric ALL patients. The fact
that this occurs from the moment of ON diagnosis, sug-
gest that the already existing BMD decline during ALL
therapy is further aggravated by restriction of weight-
bearing activities and destruction of bone architecture due
to ON.
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